Mitochondrial DNA mutations, apoptosis, and the misfolded protein response. by Mott, Justin L. et al.
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Journal Articles: Biochemistry & Molecular 
Biology Biochemistry & Molecular Biology 
2005 
Mitochondrial DNA mutations, apoptosis, and the misfolded 
protein response. 
Justin L. Mott 
University of Nebraska Medical Center, justin.mott@unmc.edu 
Dekui Zhang 
Saint Louis University 
Hans Peter Zassenhaus 
Saint Louis University 
Follow this and additional works at: https://digitalcommons.unmc.edu/com_bio_articles 
 Part of the Medical Biochemistry Commons, and the Medical Molecular Biology Commons 
Recommended Citation 
Mott, Justin L.; Zhang, Dekui; and Zassenhaus, Hans Peter, "Mitochondrial DNA mutations, apoptosis, and 
the misfolded protein response." (2005). Journal Articles: Biochemistry & Molecular Biology. 9. 
https://digitalcommons.unmc.edu/com_bio_articles/9 
This Article is brought to you for free and open access by the Biochemistry & Molecular Biology at 
DigitalCommons@UNMC. It has been accepted for inclusion in Journal Articles: Biochemistry & Molecular Biology 
by an authorized administrator of DigitalCommons@UNMC. For more information, please contact 
digitalcommons@unmc.edu. 
REJUVENATION RESEARCH
Volume 8, Number 4, 2005
© Mary Ann Liebert, Inc.
Mitochondrial DNA Mutations, Apoptosis, and the
Misfolded Protein Response
JUSTIN L. MOTT,* DEKUI ZHANG,* and HANS PETER ZASSENHAUS
ABSTRACT
Studies of transgenic mice with accelerated accumulation of mtDNA mutations specifically
in the heart lead us to propose that apoptotic signaling and cell death is central to the patho-
genesis of mtDNA mutations in aging. It is the cellular response to that apoptotic signaling
and the organ’s compensatory response to a loss of cells that specify the phenotype of an ac-
cumulation of mtDNA mutations. In the heart, cardiomyocytes induce a vigorous anti-apop-
totic, pro-survival response to counteract mitochondrial apoptotic signaling. The heart up-reg-
ulates contractility of remaining myocytes in order to maintain cardiac output. We hypothesize
that mutant mitochondrial proteins originate apoptotic signaling by interacting with proteins
already in place in the mitochondrial outer membrane that regulate apoptosis, for example
the pro-apoptotic protein Bak. Since it is unlikely that all mutant mitochondrial proteins have
the necessary structure and localization within the inner membrane to activate Bak appro-
priately, only a small fraction of an age-associated burden of mtDNA mutations may be path-
ogenic. In this model, reactive oxygen species generated by mitochondrial respiration drive
the formation of mtDNA mutations, but are not the primary mechanism for their patho-
genicity.
MITOCHONDRIAL DNA (mtDNA) mutationsaccumulate with age and disease.1 These
sporadic mutations randomly affect the mito-
chondrial genome, and thus a mutation at any
particular nucleotide position is rare. Even with
advanced age, the frequency of mutations gen-
erally does not exceed 1% in otherwise normal
individuals.2 Thus, for these mutations to cause
disease or senescence, the cell needs to be very
sensitive to mtDNA mutations. Recent evi-
dence suggests that the burden of point muta-
tions in mtDNA may be higher than previously
thought,3 so that estimates extrapolate to an av-
erage of three point mutations per genome in
the aged brain.4 Still, given the random distri-
bution of those mutations and the multiple
copies of mtDNA per mitochondrion, their ef-
fect on respiratory function would be expected
to be slight.
Despite their low frequency, mtDNA muta-
tions are still more common than nuclear DNA
mutations. Because of the compact nature of
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the mitochondrial genome, these mutations are
also more likely to affect a coding region. Due
to heterogeneity, the mutation level may be
higher in a given cell than the overall average
of the tissue.5 At the next level of compart-
mentalization, the mitochondrion itself will
have an even higher proportion of mutant
genomes. Consider a cell that has only a single
mutation on a background of maybe 1000 wild-
type mitochondrial genomes. The tissue muta-
tion level may be undetectable, the cellular mu-
tation level would be 1/1000 genomes. But the
level of the mutation in the affected mitochon-
drion would be 10–50% (given two to 10
genomes in this prototypical mitochondrion).
If mtDNA mutations contribute to disease, the
signaling mechanism must sense the high pro-
portion of mutation within a mitochondrion,
not the low proportion of a cell or tissue.
The central tenet of the mitochondrial theory
for aging is that those signals are reactive oxy-
gen species (ROS), natural byproducts of mito-
chondrial respiration.6,7 The ensuing oxidative
damage mutates mtDNA, leading in turn to
even more ROS because of malfunctioning res-
piratory enzyme complexes, all of which, with
the exception of Complex II, contain protein
subunits encoded within mtDNA.8 The “vi-
cious cycle” of ever increasing frequencies of
mtDNA mutations and oxidative damage ulti-
mately causes cellular senescence, in part be-
cause of accruing oxidative damage and in part
because of declining mitochondrial oxidative
phosphorylation.9
We argue here that apoptotic signaling is the
primary pathogenic mechanism of mtDNA
mutations in aging. It is now well established
that mitochondria play a central role in ampli-
fying cellular apoptotic signals within the in-
trinsic pathway for apoptosis.10 It is within mi-
tochondrial membranes where interactions
take place among pro- and anti-apoptotic pro-
teins such as Bak, Bax, and Bcl2 to regulate
outer membrane permeabilization and cy-
tochrome c release, unleashing the caspase cas-
cade culminating in apoptosis.11 We propose
that mutant mitochondrially encoded proteins
tap into that machinery already in place so as
to originate apoptotic signals. At any one mo-
ment, most cells sensing those signals suppress
execution of apoptosis by up-regulation of anti-
apoptotic proteins. Nevertheless, some cells
succumb. Finally, we will present a hypothesis
bearing on the molecular mechanism(s) for
how mutant proteins might originate apoptotic
signaling—a process we view as a mitochon-
drial misfolded protein response.
LITERATURE REVIEW
Transgenic mice with accelerated accumulation of
mtDNA mutations
In order to fully develop this hypothesis, we
will review recent results from a mouse model
that accumulates mitochondrial DNA muta-
tions at an accelerated rate. Transgenic mice
were generated that accelerate accumulation of
mtDNA mutations specifically in the heart be-
cause of the expression of a proof-reading de-
ficient pol g, the mtDNA polymerase.12 Since
the a-myosin heavy chain promoter driving 
expression of the transgene turns on only 
after birth, developmental abnormalities are
avoided which might otherwise arise from fe-
tal expression of the transgene. Likewise, since
expression is restricted to cardiomyocytes,
pathogenesis in the heart is not complicated by
dysfunction in other organ systems, which
could impact on cardiac function. This poten-
tially confounding situation is of course inher-
ent to characterizations of aged versus young
animals or individuals. Similar interpretive dif-
ficulties are present with the recently reported
knockin mouse where the wild-type pol g has
been replaced by a proof-reading deficient ver-
sion.13,14 In that model, mtDNA mutations are
generated in all tissues, presumably from early
embryogenesis onwards, it is more difficult to
distinguish pathology arising directly from
mtDNA mutations within a specific tissue from
pathology secondary to homeostatic imbal-
ances in the animal.
In our transgenic mice, mtDNA mutations
rapidly accumulate specifically in the heart
from birth onwards. By 1 month of age, point
mutations reach levels of one per 10,000 bp of
mtDNA, determined by DNA sequencing of
cloned fragments generated without PCR am-
plification. By 3 months of age, mutation fre-
quencies climb to 1.5 per 10,000 bp, represent-
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ing on average two point mutations per
mtDNA molecule. Mutations are randomly
scattered around the mitochondrial genome
and 5–10-fold higher than in wild-type animals.
Humans and rodents also accumulate large
scale deletion mutations in mtDNA with
age.15,16 These transgenic mice do likewise.
Thus, at the DNA level these mice recapitulate,
albeit at an accelerated pace, features of
mtDNA mutations found in aging humans and
rodents.
Cardiac pathology is first observed in these
transgenic mice at about 1 month of age.17
Transgenic animals invariably develop a four-
chamber dilated cardiomyopathy, atrial throm-
bosis, fibrosis, and histologically apparent cell
death.17 Conditions deteriorate over time so
that animals rarely live beyond 11/2 years of
age, with terminal signs and symptoms con-
sistent with end-stage heart failure. Even at
younger ages (1–2 months) some animals de-
velop congestive heart disease and experience
sudden death.
The severe pathology observed in these mice
seems to be inconsistent with the relatively be-
nign frequencies of mtDNA mutations (i.e., ,1
mutation per 10,000 bp), raising concerns that
artifacts associated with the transgene may be
responsible for pathology, rather than the mu-
tations themselves. Insertional mutagenesis of
a specific nuclear gene by the transgene itself
appears not to be involved since two indepen-
dent lines show essentially identical pheno-
types. Although transgene expression is some
2–4-fold higher than endogenous pol g in wild-
type animals, transgenic animals expressing a
normal version of pol g at similar levels, 
driven by the same a-MHC promoter, show no
cardiac pathology and no accumulation of
mtDNA mutations.17 DNA sequencing of the
entire transgene used for construction of trans-
genic mice, including sequences recovered by
PCR amplification from mouse chromosomal
DNA, show no second site alterations (unpub-
lished data). In the transgenic heart, mtDNA
content does not differ from control littermates,
indicating minimal effects of the mutant proof-
reading domain on the catalytic property of the
enzyme.12 This is consistent with studies where
we showed that expression of the mutant ver-
sus wild-type transgene in cos cells yielded
mtDNA polymerases with similar DNA syn-
thetic activity, but as expected, the mutant en-
zyme lacked 39 exonuclease activity.12 Impor-
tantly, cardiac pathology in transgenic animals
correlates with the rise in the frequency of
mtDNA mutations rather than with expression
of the transgene. By day 2 after birth, transgene
expression is maximal, yet for the first 3–4
weeks of life cardiac structure appears to be
completely normal at the gross and histologi-
cal level.17
Finally, we now better appreciate that a fre-
quency of point mutations of about two per ge-
nome may not be so benign.18 As pointed out
in the Introduction, the aging human brain is
estimated to have about three point mutations
per genome, and this is considered a high bur-
den. Similar to our mice, knockin mice ex-
pressing proof-reading deficient pol g in all tis-
sues have point mutation frequencies in the
heart about 4–6-fold higher than wild-type con-
trols.13,14 These mice similarly develop a di-
lated cardiomyopathy. What these mouse
models force us to face is that seemingly low
frequencies of randomly generated mtDNA
mutations are indeed pathogenic. They provide
a strong counterweight to those arguing that
the age-related rise in mtDNA mutations is an
epiphenomenon, not being high enough to
cause either disease or physiological senes-
cence.19,20
No decreased respiration or increased 
oxidative stress
We first tested the hypothesis that pathology
arose due to either decreased mitochondrial
respiration or increased oxidative stress. We fo-
cused on animals 1–2 months of age, when
pathology was first apparent so as to minimize
potential complications secondary to long-
standing disease. No evidence was found for
either process.12,17,21 Specifically, with regards
to respiration:
1. By polarography, isolated mitochondria
from transgenic hearts showed no declines
in respiration rates or P:O ratios with a va-
riety of substrates.12,17,21
2. Mitochondrial content of cytochromes was
normal.12,17,21
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3. Specific activities of the cytochrome oxidase,
NADH-dehydrogenase, and ATP syn-
thetase were normal17,21 (and unpublished
data).
4. Substrate driven increases in the transmem-
brane potential of isolated mitochondria
were normal.12,17,21
5. By western blotting, the content was normal
for cytochrome c and cox4, a mitochondri-
ally encoded subunit of cytochrome oxi-
dase.17
Furthermore, indirect evidence for a decline
in respiratory function was lacking. The con-
tent of ATP was not lower in the transgenic
heart; indeed, it was somewhat elevated.17 In
patients with mtDNA mutations high enough
to compromise oxidative phosphorylation,
compensatory responses up-regulate both mi-
tochondrial gene expression and number.22 By
Northern blotting12,17,21 and electron micro-
scopy,17 neither of those compensatory re-
sponses was seen in transgenic hearts. Indeed,
our collaborator performing the ultrastructural
analysis of tissue sections from 6-week-old an-
imals could not distinguish transgenic from lit-
termate controls when blinded to their identity.
Specifically with regards to oxidative stress:
1. No increases were seen in the transgenic heart
of either 8-OH-dG adducts in mtDNA or cel-
lular and mitochondrial protein carbonyls,
both indicators of oxidative damage.21
2. Glutathione levels and the ratio of GSH/
GSSG were unaltered.21
3. Total and specific activities of mitochondrial
aconitase, an enzyme highly sensitive to ox-
idative damage, were normal.21
4. Upregulation of anti-oxidant defenses (e.g.,
copper/zinc superoxide dismutase, glu-
tathione peroxidases) was not seen, either by
immunohistochemistry21 or by microarray
analysis.23
5. Activation was not seen of signaling path-
ways responsive to oxidative stress (e.g.,
MAPK, SAPK/JNK, NFkB [unpublished
data]).
6. Recent data from a separate model of in-
creased mitochondrial DNA mutations in
the whole-animal confirm that there is no in-
creased oxidative stress.14
Collectively, the conclusion seems inescapable
that elevated frequencies of mtDNA mutations
in this model cause pathology by a mechanism
not directly related to disturbances in the func-
tion of the electron transport chain.
MtDNA mutations induce a pro-survival
response at the cellular level
At 1 month of age, when mice first show car-
diac dilation, a surge of apoptosis occurs in the
heart so that, at its peak, about one in 50 car-
diomyocytes are TUNEL positive.17 Histologi-
cally, degenerating cells and cell drop-outs are
visible by hematoxylin-eosin staining. In-
creased levels of cytosolic cytochrome c indi-
cate mitochondrial involvement in the apop-
totic signaling. But apoptosis wanes over the
ensuing weeks, so that by 8–10 weeks of age,
frequencies of TUNEL-positive cells are only
slightly higher than that of controls.17 Likewise,
cytosolic levels of cytochrome c decline but 
remain still slightly greater than controls. The
decline in apoptosis correlates with a cellular
pro-survival response,17,24,25 a coordinated up-
regulation of multiple anti-apoptotic proteins,
including Bcl2, Bfl1, Bcl-XL, XIAP, and Hsp27,
which function to suppress programmed cell
death at various steps in the intrinsic pathway
of apoptosis.26,27 This pro-survival response per-
sists for the life of the animal, possibly because
pro-apoptotic signaling persists, as evidenced
by cytochrome c release and mitochondrial as-
sociated Bax. Importantly, the pro-survival re-
sponse occurs in all cardiomyocytes within the
heart, as shown by immunohistochemistry for
Bcl2 and Hsp27.17 It places the heart in a pro-
tective state against insults provoking cell
death,25 such as doxorubicin, a cardiotoxin that
causes apoptosis of cardiomyocytes.28
These results tell us that, at the cellular level,
increased frequencies of mtDNA mutations
provoke apoptotic signaling. Even at its peak,
however, levels of cytosolic cytochrome c in the
transgenic heart are less than 5% of the total,
suggesting that only a small fraction of mito-
chondria release cytochrome c at any one time.
This is consistent with cell culture studies in-
dicating that cytochrome c release is an all-or-
none phenomenon at the mitochondrial level.29
The implication is that it may not be the cellu-
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lar burden of mtDNA mutations per se that is
pathogenic, but rather either a threshold level
in some mitochondria or a specific mutation in
particular mitochondria. Since cardiomyocytes
contain thousands of mitochondria, each har-
boring several mtDNA molecules, some mito-
chondrion somewhere in the cell is bound to
harbor any specific mutation when the global
average of random mutations climbs to ,2 per
genome. The unfortunate few who have an
apoptosis-signaling mutation, however, have a
disproportionate effect on the entire popula-
tion because of the cellular pro-survival re-
sponse, which, for instance, places high levels
of Bcl2 on all mitochondria.25
It is the pro-survival response that represents
an important aspect of the pathogenesis of an
age-associated rise in mtDNA mutations. Bcl2
in the endoplasmic and sarcoplasmic reticulum
has been reported to alter permeability to cal-
cium.30 Enforced over-expression of Bcl2 in the
mouse heart inhibits the mitochondrial so-
dium-calcium exchanger and inhibits opening
of the mitochondrial permeability transition
pore.31 Higher levels of Bcl-XL, Bfl1, XIAP,
Hsp27, and other participants in the pro-sur-
vival response would likewise be expected to
affect cellular functions. Thus, the pro-survival
response provoked by pro-apoptotic signaling
from a few mitochondria is one mechanism for
amplifying the pathogenic potential of a rela-
tively low global average of mtDNA mutations
in a cell. At the moment, we do not know what
the molecular signaling pathways in cardio-
myocytes are that up-regulate expression of
Bcl2 and other genes involved in the pro-sur-
vival response.
Cardiomyocytes in a pro-survival state have
enhanced physiological function
Is the pro-survival response acutely patho-
logic for cardiomyocytes? To address that ques-
tion, we isolated single cells from dilated hearts
2–3 months of age and measured their contrac-
tility upon field stimulation at pacing frequen-
cies of 0.5–4 Hz (Zhang et al., submitted). Sur-
prisingly, transgenic cells have much greater
contractility than control cells, showing nearly
1.8-fold greater fractional shortening than con-
trols at all pacing frequencies. Increased storage
of calcium in the sarcoplasmic reticulum and
increased release of calcium during the tran-
sient after electrical stimulation appear to play
an important role in that increased contractil-
ity. This hypercontractility indicates that trans-
genic cardiomyocytes are not physiologically
dysfunctional or senescent, despite having
higher levels of mtDNA mutations and despite
being in a pro-survival state. These results
seem paradoxical in that the heart is dilated
and diseased, yet the cells therein are func-
tioning at a supraphysiological level. The res-
olution to that paradox rests in the observation
that, by 3 months of age, the transgenic heart
has about 45% fewer cardiomyocytes than lit-
termate controls (Zhang et al., submitted). Pre-
sumably, this is a consequence of the low lev-
els of persistent apoptosis in the transgenic
heart. Hypercontractility of the remaining cells,
then, is a compensatory response of the heart
to maintain cardiac output in the setting of a
much reduced cell number. Whether that hy-
percontractility response is mechanistically re-
lated to or independent of the pro-survival re-
sponse is unknown at the moment.
These results provide a new framework for
viewing the pathogenesis of elevated levels of
mtDNA mutations in the heart with age. As
the burden of random mtDNA mutations
rises, a few mitochondria within a cell happen
to suffer the “right” mutation and initiate pro-
apoptotic signaling. In cells with large num-
bers of mitochondria, such as cardiomyocytes, 
eventually all cells are affected. Although a 
vigorous anti-apoptotic, pro-survival re-
sponse mostly suppresses execution of the
apoptotic command, some cells succumb nev-
ertheless. However, new mtDNA mutations
continue to be generated with age, and the
burden of mtDNA mutations inexorably
climbs. Cells continue to be lost. The heart
compensates for the lost cells by up-regulat-
ing the physiological function of the remain-
ing cells. But eventually in a post-mitotic or-
gan that compensation is limited, leading to
either disease or physiological dysfunction at
the organ level. The evoked pro-survival re-
sponse in the absence of cell death may also
by itself be maladaptive in the long term. This
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model, then, views apoptotic signaling as the
primary pathogenic mechanism for rising lev-
els of mtDNA mutations.
Role of ROS
In distinction to the free radical theory of ag-
ing, this model for the pathogenesis of an age-
related rise in mtDNA mutations does not 
directly implicate generation of ROS as the pri-
mary mechanism for their pathogenicity. How-
ever, oxidative damage still plays an important
role. It is likely that in normal individuals ox-
idative damage is the main driving force for the
generation of mtDNA mutations in the first
place, resulting from the ROS generated by mi-
tochondrial respiration. It would be interesting
to know whether the pro-survival response it-
self, or other cellular compensatory responses
that are invoked to maintain physiological
function of the organ, have direct effects on
ROS generation as well.
An apoptotic model for the pathogenesis of
mtDNA mutations has implications for re-
search using model systems to study their ef-
fects. If only rare, “correct” mtDNA muta-
tions generate mutant proteins capable of
interacting with the apoptotic machinery so
as to signal apoptosis, then those pathogenic
mutations would tend to be lost from a tissue
as it ages and cells die. A powerful strategy
to study the pathology of mtDNA mutations
that are present in aged or diseased tissues is
to fuse enucleated cells taken from such
donor tissues with recipient cells in culture
lacking mtDNA (i.e., rho0 cells).32 Even if the
pro-survival response mostly suppresses
apoptosis, allowing apoptosis-signaling mu-
tations to persist longer than they would oth-
erwise, cytoplasmic hybrids (cybrids) recon-
stituted with mitochondria from such tissues
may not invoke a pro-survival response, ei-
ther at all or fast enough. Again, by the time
the cybrid cultures are established, the path-
ogenic mtDNA mutations might be lost. In an
ironic twist, those who argue that age-associ-
ated mtDNA mutations are an epiphenome-
non—a consequence of aging but not its
cause—may be right. Not because mutagene-
sis of mtDNA is hardly high enough to be
pathogenic, but because the pathogenic mu-
tations are lost over time as cells die, leaving
behind those mutations with little or reduced
pathogenicity.
Mitochondrial permeability transition pore as a
target for mtDNA mutations
This model then directs attention to how
mtDNA mutations, or more accurately mutant
mitochondrial proteins, originate apoptotic sig-
naling (i.e., outer membrane permeabilization
and release of cytochrome c). One such target
may be the mitochondrial permeability transi-
tion pore (mPTP). This pore is a channel that
spans the mitochondrial inner and outer mem-
branes and is thought to be comprised of a com-
plex of proteins including the voltage depen-
dent anion channel located in the outer
membrane and the adenine nucleotide translo-
cator located in the inner membrane33 (for fur-
ther complexities on the structure of the pore,
see others34,35). Pore opening breaks down the
osmotic barrier, which then leads to mitochon-
drial swelling, rupture of the outer membrane,
and cytochrome c release.36 Within the mito-
chondrial matrix, the activity of cyclophilin D
(CyP D) facilitates pore opening.37 Cyp D is a
chaperone having peptidyl-prolyl cis-trans iso-
merase activity and is the major cyclosporin A
(CsA) binding protein within mitochondria.38
CsA is a potent inhibitor of pore opening.39 In
rodent models for ischemic and traumatic brain
injury and cardiac injury following ischemia-
reperfusion, CsA treatment protects against
neuronal and myocytic cell death,40–42 sug-
gesting that pore opening plays an important
role in the apoptosis observed in those models.
However, pore opening is not obligatory for cy-
tochrome c release and apoptosis in all cir-
cumstances. Cells in culture can release cy-
tochrome c and initiate apoptosis without pore
opening,43 reflecting perhaps the intrinsic abil-
ity of pro-apoptotic proteins such as Bak and
Bax to form channels within the outer mem-
brane large enough for cytochrome c to es-
cape.11,44,45
In order to determine if the pore is a target
for apoptotic signaling arising from mtDNA
mutations, we treated our transgenic mice with
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CsA starting at 3 weeks of age (before disease
is apparent) and continuing out to 6 weeks of
age (when disease is well established).46 CsA
treatment completely prevented the develop-
ment of cardiac dilation. Mutation-induced
apoptosis was prevented, as was the induction
of the pro-survival response, as indicated by
the failure of Bcl2 to be up-regulated. Another
aspect of the cardiomyopathy in these trans-
genic mice is profound down-regulation of 
the gap junction protein, connexin 43.46 CsA
treatment prevented that down-regulation as
well. Control animals treated with FK506
(which, like CsA, inhibits cytoplasmic calci-
neurin activity, an important regulator of my-
ocytic function, but unlike CsA does not inhibit
mitochondrial Cyp D) showed none of the pro-
tective effects seen with CsA.46
These data implicate Cyp D function as nec-
essary for the pathogenicity of elevated levels
of mtDNA mutations. Is that function its facil-
itation of mPTP opening, implying that mutant
mitochondrial proteins activate CyP D, so as to
potentiate pore opening? In the transgenic
heart, Cyp D is found associated with the mi-
tochondrial inner membrane (unpublished
data), a feature that is linked with potentiation
of pore opening.47,48 Calcium overload is a po-
tent trigger of pore opening,49 manifested in
vitro as a concentration-dependent dissipation
of the mitochondrial transmembrane potential.
Transgenic mitochondria show resistance to
pore opening (Mott et al., submitted). This re-
sistance to pore opening is not what we would
have expected if mutant mitochondrial pro-
teins potentiate pore opening, similar to, for ex-
ample, the effects of oxidant treatment on iso-
lated mitochondria.47,50
Further studies indicated that this resistance
is a consequence of the pro-survival response.
Bcl2 in mitochondrial membranes inhibits pore
opening.31,51 In our transgenic animals, resis-
tance to pore opening correlates in time with
the up-regulation of Bcl2, which we know in-
cludes 5–10-fold higher levels of Bcl2 in mito-
chondrial membranes.25 Finally, pore opening
in transgenic mitochondria is normalized by
treatment with peptides whose sequences de-
rive from the BH3 domains of Bax and Bid
(Mott et al., in preparation). Bax and Bid bind
Bcl2 through their BH3 domains,52 and pep-
tides derived from those sequences interfere
with the ability of Bcl2 to protect against pore
opening and cytochrome c release.53,54 These
findings indicate that pore dysfunction in trans-
genic mitochondria is due to up-regulation of
Bcl2—and that pore dysfunction is one of the
consequences of the pro-survival response. They
suggest that potentiation of pore opening is not
the mechanism driving apoptotic signaling by
mutant mitochondrial proteins.
HYPOTHESIS
Molecular mechanism of apoptotic signaling by
mtDNA mutations
If it isn’t the pore, then what is the target for
mutant mitochondrial proteins? CsA treatment
of these animals strongly protects against devel-
opment of disease and prevents apoptotic sig-
naling. We suggest that it is inhibition of the
chaperone function of CyP D by CsA, not inhi-
bition of its pore-opening function, that abro-
gates apoptotic signaling of mutant mitochondr-
ial proteins. All mitochondrial-encoded proteins
are integral membrane subunits of the respira-
tory enzyme complexes, whose assembly and in-
sertion into the inner membrane require the ac-
tivity of chaperones.55 CyP D activity enhances
the kinetics of assembly,56,57 although its activ-
ity seems not to be essential, most elegantly dem-
onstrated by the recent reports of CyP D null
mice in which mitochondrial function (aside
from pore opening) appears to be quite nor-
mal.58–60 Thus, inhibition of CyP D chaperone ac-
tivity by CsA would be expected to at least de-
lay the translocation of newly made mutant
mitochondrial proteins into the inner membrane.
Since misfolded mutant proteins within mito-
chondria are degraded more rapidly than their
wild-type counterparts,61–63 this delay by itself
may be sufficient to substantially reduce the lev-
els of mutant proteins inserted into the mito-
chondrial inner membrane.
If inserted into the inner membrane, mutant
mitochondrial proteins would be poised to ac-
tivate latent pro-apoptotic proteins. One such
candidate is Bak, a resident integral outer mem-
brane protein, whose conformational activation
results in oligomerization, permeabilization of
the outer membrane, release of cytochrome c,
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and apoptosis.64 Since it is unlikely that simply
any mutant protein has the necessary structure
to interact appropriately with Bak, stochastic
mutagenesis of mtDNA would need to con-
tinue for some time so as to have a reasonable
probability of generating the appropriate mu-
tant. Recall that we earlier suggested that it
may not be the burden of mutations per se that
triggers apoptosis with aging, but rather spe-
cific rare mutants. Thus, apoptotic signaling
may derive only from specific mutations in
some mitochondrial genes, perhaps only those
whose mutant protein product is situated
within the inner membrane in such a way so
as to be able to interact with Bak.
Mitochondrial misfolded protein response
We term this postulated mechanism for 
the pathogenicity of mutant mitochondrial pro-
teins the mitochondrial misfolded protein 
response. The hypothesis that misfolded mito-
chondrial proteins originate apoptotic signal-
ing has several attractive features. First, the
level of misfolded proteins would be a sensi-
tive indicator of stress. Remember the example
given in the Introduction of a cell with one mu-
tation in a 1000; a respiratory decrease would
be all but undetectable. By detecting a positive
signal over a low background (misfolded pro-
teins), the misfolded response would be sensi-
tive to this low level of damage. Amplification
of its impact on cellular function would follow
from the pro-survival response. Further, the of-
fending mutation would not be ignored
through the complementing gene product of
another mitochondrial genome in the same or-
ganelle. Another feature of this response sys-
tem is that the insult need not necessarily de-
rive from mtDNA mutations. Other stresses
can cause misfolding, including heat stress and
oxidative damage. In the case of oxidative
stress, it would be efficient to have a detector
of ROS in close proximity to a major generator
of ROS, the electron transport chain. Finally,
the sensitivity of the cellular response to mis-
folded proteins could be fine tuned to the de-
mands of the cell via regulation by protective
proteins like Bcl2. So, for example, the mater-
nal germ cell would be a cell where a low sig-
nal from mitochondria activates cell death, con-
tributing to the high rates of atresia and apop-
tosis during oocyte development.65 Having
high sensitivity would help ensure that new-
borns are remarkably free of mutations.66 There
are likely additional safeguards in develop-
ment that are beyond the scope of this review,
including a mitochondrial genetic bottleneck.67
Still, some mutations would bypass detection
by the mitochondrial misfolded protein re-
sponse, as they would not result in misfolded
proteins (e.g., deletion mutations which com-
pletely inactivate mitochondrial translation).
Some potential examples of mutations that by-
pass selection are inherited mitochondrial
myopathies68 and common polymorphisms.69
Testing the hypothesis
This apoptotic model for the pathogenesis of
mtDNA mutations makes some testable pre-
dictions:
1. Pathology in mice expressing a proof-read-
ing deficient pol g should be ameliorated
when the transgene is placed on a back-
ground null for CyP D or Bak. Null mice for
both of those proteins are available.59,70 In-
deed, CyP D and Bak null mice, which by
themselves show remarkably little pathol-
ogy, might show increased longevity since
the apoptotic pathogenicity of mtDNA mu-
tations has been blunted.
2. Cybrids reconstituted with mitochondria
from aged tissues might reveal the apoptotic
potential of mtDNA mutations in the tissue
if the cybrid recipients over-express Bcl2 un-
der control of a regulatable promoter. Once
established under high Bcl2 expression,
down-regulating Bcl2 in these cultures may
trigger a wave of apoptosis. The underlying
assumption here is that cells from aging tis-
sues retain mitochondria with apoptotic sig-
naling mutations because of up-regulation
of a pro-survival response.
3. Placing transgenic mice with rapid accumu-
lation of mtDNA mutations on a Bcl2-defi-
cient background should greatly increase
the pathogenicity of mtDNA mutations. Pre-
liminary results with our transgenic mice in-
dicate that this is indeed the case.
4. Finally, centenarians might exhibit poly-
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morphisms in the genes for CyP D or Bak
that result in reduced transduction of the
pathogenicity of mtDNA mutations.
CONCLUSION
It needs to be remembered that aging is a
complex, multifactorial process. This apoptotic
signaling hypothesis addresses the patho-
genicity of only point mutations in mitochon-
drial protein genes. We know that point muta-
tions in tRNA genes and massive deletion
mutations also accumulate with age, which
have the potential to completely prevent trans-
lation in affected mitochondria. Their patho-
genicity would be expected to involve differ-
ent mechanisms. In aging tissues, cells with a
heterogeneous spectrum of mutational types
and amounts are likely to be present resulting
in a complex interplay of pathologies. Our hy-
pothesis hopefully will focus attention on
apoptotic signaling so as to better determine its
role in driving the aging process.
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